利福平粉针剂治疗初治涂阳肺结核近期疗效观察

目的 观察利福平粉针剂治疗初治涂阳肺结核的近期疗效和安全性。方法80例初治涂阳肺结核患者随机分为两组,治疗组（n=40）和对照组（n=40）强化期分别用异烟肼（H）、吡嗪酰胺（Z）、乙胺丁醇（E）加利福平粉针剂和HZE加利福平胶囊方案治疗;观察治疗第1个月和第2个月末痰菌阴转率、X线吸收率及药物不良反应。结果治疗第1和第2个月末,治疗组强化期末及疗程结束时痰菌阴转率分别为84．6％和92．3％,对照组为81．6％和92．1％,两组经比较差异均元统计学意义（P〉0．05）;胸片病灶吸收率分别为84．6％和84．2％,经比较差异均无统计学意义（P〉0．05）。治疗组副反应总发生率为25．6％,对照组为55．3％,两组比较差异有显著统计学意义（P〈0．01）。结论利福平粉针剂治疗初治涂阳肺结核的近期效果与利福平胶囊疗效相当,是治疗肺结核安全有效的药物剂型之一,但其副反应较利福平胶囊小,病人耐受性较好。

The initial bacterium-male pulmonary tuberculosis treated by rifampicin(RFP)injectable powder

Objective To observe the efficacy and safety of initial bacterium - male pulmonary tuberculosis with RFP injectable powder. Methods 80 patients of initial bacterium - male pulmonary tuberculosis were randomly divided into two group, trial group（40 patients） treated with HZE and RFP injectable powder, control group（40 patients） with HZE and RFP capsule, and the sputum negative conversion rate, X -ray absorption rate, drug adverse reaction were observed after one month and two months treatment. Results The sputum negative conversion rate of trial group was 84.6% in one month, and 92.3% in second month. The sputum negative conversion rate of control group was 81.6% in one month, and 92.1% in second month and there was no significant difference. X - ray absorption rate was 84.6% and 84.2% in second month, and there was no significant difference. The rate of drug adverse reaction is 25.6% and 55.3%, and there was significant difference. Condusion RFP injectable powder and RFP capsule have same efficacy, but RFP injectable powder has the lower rate of drug adverse reaction and better tolerance compared with RFP capsule.